SCHEMBL5653478

SCHEMBL5653478

NC(=O)c1[nH]ccc1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.41
NAPRT Q6XQN6 1/20 0.41
PDPK1 O15530 1/20 0.40
KDM4E B2RXH2 5/20 0.39
MAPT P10636 2/20 0.39
GAA P10253 1/20 0.39
IKBKB O14920 2/20 0.38
CHUK O15111 2/20 0.38
ALDH1A1 P00352 4/20 0.37
ALOX15 P16050 1/20 0.37
CYP1A2 P05177 1/20 0.37
KMT2A Q03164 2/20 0.36
GDA Q9Y2T3 1/20 0.36
HSD17B10 Q99714 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
POLB P06746 1/20 0.34
CYP3A4 P08684 1/20 0.34
PARP1 P09874 1/20 0.34
TSHR P16473 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7926845 0.86 PDPK1 (0.47) PDPK1KDM4EMAPTIKBKBCHUK
SCHEMBL69690 0.86 KEAP1 (0.47) KEAP1NAPRTKDM4EMAPTGAA
SCHEMBL27517115 0.86 NAPRT (0.50) KEAP1NAPRTPDPK1KDM4EMAPT
SCHEMBL29158222 0.81 CSNK1A1 (0.40) PDPK1IKBKBCHUKALDH1A1GDA
SCHEMBL29042806 0.78 RAB9A (0.41) KEAP1NAPRTKDM4EMAPTGAA
SCHEMBL311990 0.77 KEAP1 (0.40) KEAP1NAPRTKDM4EMAPTGAA
SCHEMBL5173735 0.75
SCHEMBL27820698 0.74 CNR2 (0.42) KEAP1NAPRTKDM4EMAPTGAA
SCHEMBL562266 0.73
SCHEMBL6672416 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191349-A1 C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4] benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs therof as well as related compounds for the treatment of proliferative diseases SPIROGEN LIMITED (GB) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191349-A1 C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4] benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs therof as well as related compounds for the treatment of proliferative diseases TSPO, GABRD, BCOR KEAP1 1560/4885NAPRT 710/4885PDPK1 4209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.